Bioventus Inc.
BVS
$7.64
$0.567.91%
NASDAQ
| 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 147.66M | 123.88M | 153.64M | 138.96M | 151.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 147.66M | 123.88M | 153.64M | 138.96M | 151.22M |
| Cost of Revenue | 45.57M | 40.82M | 50.99M | 45.41M | 47.58M |
| Gross Profit | 102.09M | 83.06M | 102.66M | 93.55M | 103.64M |
| SG&A Expenses | 79.10M | 73.48M | 86.53M | 81.04M | 84.17M |
| Depreciation & Amortization | 1.44M | 1.59M | 1.77M | 2.07M | 2.06M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.28M | 118.90M | 142.53M | 132.33M | 138.02M |
| Operating Income | 18.38M | 4.97M | 11.11M | 6.64M | 13.20M |
| Income Before Tax | 10.31M | -3.42M | 232.00K | -4.83M | -41.56M |
| Income Tax Expenses | 1.04M | -95.00K | 550.00K | 589.00K | -7.34M |
| Earnings from Continuing Operations | 9.27M | -3.32M | -318.00K | -5.42M | -34.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.81M | 685.00K | 162.00K | 597.00K | 8.54M |
| Net Income | 7.46M | -2.64M | -156.00K | -4.82M | -25.68M |
| EBIT | 18.38M | 4.97M | 11.11M | 6.64M | 13.20M |
| EBITDA | 30.43M | 16.84M | 15.90M | 18.91M | 26.29M |
| EPS Basic | 0.11 | -0.04 | 0.00 | -0.07 | -0.40 |
| Normalized Basic EPS | 0.07 | -0.02 | 0.03 | -0.01 | 0.16 |
| EPS Diluted | 0.11 | -0.04 | 0.00 | -0.07 | -0.40 |
| Normalized Diluted EPS | 0.07 | -0.02 | 0.03 | -0.01 | 0.16 |
| Average Basic Shares Outstanding | 66.50M | 66.01M | 65.45M | 65.26M | 64.06M |
| Average Diluted Shares Outstanding | 68.54M | 66.01M | 65.45M | 65.26M | 64.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |